BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
BNT162b2
IgA
IgG
SARS‐CoV‐2
mucosal immunity
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: Germany
ID NLM: 101487380
Informations de publication
Date de publication:
19 Apr 2022
19 Apr 2022
Historique:
received:
22
10
2021
accepted:
01
04
2022
revised:
29
03
2022
medline:
19
4
2022
pubmed:
19
4
2022
entrez:
24
10
2024
Statut:
epublish
Résumé
Vaccination against an airborne pathogen is very effective if it induces also the development of mucosal antibodies that can protect against infection. The mRNA-based vaccine-encoding SARS-CoV-2 full-length spike protein (BNT162b2, Pfizer/BioNTech) protects also against infection despite being administered systemically. Here, we show that upon vaccination, cognate IgG molecules are also found in the saliva and are more abundant in SARS-CoV-2 previously exposed subjects, paralleling the development of plasma IgG. The antibodies titer declines at 3 months from vaccination. We identified a concentration of specific IgG in the plasma above which the relevant IgG can be detected in the saliva. Regarding IgA antibodies, we found only protease-susceptible IgA1 antibodies in plasma while they were present at very low levels in the saliva over the course of vaccination of SARS-CoV-2-naïve subjects. Thus, in response to BNT162b2 vaccine, plasma IgG can permeate into mucosal sites and participate in viral protection. It is not clear why IgA1 are detected in low amount, they may be proteolytically cleaved.
Identifiants
pubmed: 39443720
doi: 10.15252/emmm.202115326
pii: 10.15252/emmm.202115326
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
EMMM202115326Subventions
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : COVID-2020-12371640
Informations de copyright
© 2022. The Author(s).
Références
Abu Jabal K, Ben‐Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, Edelstein M (2021) Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID‐19 vaccine: real‐world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill 26: 2100096
Ali F, Sweeney DA (2021) No one likes a stick up their nose: making the case for saliva‐based testing for coronavirus disease 2019 (COVID‐19). Clin Infect Dis 72: e357–e358
Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J et al (2020) A serological assay to detect SARS‐CoV‐2 seroconversion in humans. Nat Med 26: 1033–1036
Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Ietto G, Iovino D, Baj A, Gianfagna F, Maurino V, Focosi D et al (2022) Mucosal immune response in BNT162b2 COVID‐19 vaccine recipients. EBioMedicine 75: 103788
Baeza‐Yates R, Ribeiro‐Neto B (1999) Modern information retrieval. New York, NY: ACM Press
Bradley EC, Tibshirani RJ (1994) An introduction to the bootstrap. Boca Raton, FL: CRC Press
Brandtzaeg P (2007) Do salivary antibodies reliably reflect both mucosal and systemic immunity? Ann N Y Acad Sci 1098: 288–311
Cerutti A, Rescigno M (2008) The biology of intestinal immunoglobulin A responses. Immunity 28: 740–750
Chan RWY, Liu S, Cheung JY, Tsun JGS, Chan KC, Chan KYY, Fung GPG, Li AM, Lam HS (2021) The mucosal and serological immune responses to the novel coronavirus (SARS‐CoV‐2) vaccines. Front Immunol 12: 744887
Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, Al Khatib HA, Coyle P, Ayoub HH, Al Kanaani Z et al (2021) Waning of BNT162b2 vaccine protection against SARS‐CoV‐2 infection in Qatar. N Engl J Med 385: e83
Collie S, Champion J, Moultrie H, Bekker LG, Gray G (2022) Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med 386: 494–496
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M, Reis B, Balicer RD (2021) BNT162b2 mRNA Covid‐19 vaccine in a nationwide mass vaccination setting. N Engl J Med 384: 1412–1423
Guerrieri M, Francavilla B, Fiorelli D, Nuccetelli M, Passali FM, Coppeta L, Somma G, Bernardini S, Magrini A, Di Girolamo S (2021) Nasal and salivary mucosal humoral immune response elicited by mRNA BNT162b2 COVID‐19 vaccine compared to SARS‐CoV‐2 natural infection. Vaccines (Basel) 9: 1499
Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang YM et al (2020) Persistence of serum and saliva antibody responses to SARS‐CoV‐2 spike antigens in COVID‐19 patients. Sci Immunol 5: eabe5511
Klingler J, Lambert GS, Itri V, Liu S, Bandres JC, Enyindah‐Asonye G, Liu X, Simon V, Gleason CR, Kleiner G et al (2021) Detection of antibody responses against SARS‐CoV‐2 in plasma and saliva from vaccinated and infected individuals. Front Immunol 12: 759688
Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez‐González MC, Bielak DA, Carreño JM, Chernet RL et al (2021) Antibody responses in seropositive persons after a single dose of SARS‐CoV‐2 mRNA vaccine. N Engl J Med 384: 1372–1374
Kwon T, Gaudreault NN, Richt JA (2021) Seasonal stability of SARS‐CoV‐2 in biological fluids. Pathogens 10: 540
Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, Rescigno M (2021) A cautionary note on recall vaccination in ex‐COVID‐19 subjects. medRxiv https://doi.org/10.1101/2021.02.01.21250923 [PREPRINT]
doi: 10.1101/2021.02.01.21250923
Lue C, Tarkowski A, Mestecky J (1988) Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti‐pneumococcal antibodies. J Immunol 140: 3793–3800
Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P (2008) The immune geography of IgA induction and function. Mucosal Immunol 1: 11–22
Mantis NJ, Rol N, Corthésy B (2011) Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 4: 603–611
Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, Klein SL, Betenbaugh MJ, Clarke WA, Laeyendecker O et al (2020) COVID‐19 serology at population scale: SARS‐CoV‐2‐specific antibody responses in saliva. J Clin Microbiol 59: e02204‐20
Risk M, Shen C, Hayek SS, Holevinski L, Schiopu E, Freed G, Akin C, Zhao L (2022) Comparative effectiveness of COVID‐19 vaccines against the Delta variant. Clin Infect Dis https://doi.org/10.1093/cid/ciac106
doi: 10.1093/cid/ciac106
Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM (2021) Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS‐CoV‐2. JAMA 325: 1467–1469
Samanovic MI, Cornelius AR, Wilson JP, Karmacharya T, Gray‐Gaillard SL, Allen JR, Hyman SW, Moritz G, Ali M, Koralov SB et al (2021) Poor antigen‐specific responses to the second BNT162b2 mRNA vaccine dose in SARS‐CoV‐2‐experienced individuals. medRxiv https://doi.org/10.1101/2021.02.07.21251311 [PREPRINT]
doi: 10.1101/2021.02.07.21251311
Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, Quentric P, Fadlallah J, Devilliers H, Ghillani P et al (2021) IgA dominates the early neutralizing antibody response to SARS‐CoV‐2. Sci Transl Med 13: eabd2223
To K‐W, Tsang O‐Y, Leung W‐S, Tam AR, Wu T‐C, Lung DC, Yip C‐Y, Cai J‐P, Chan J‐C, Chik T‐H et al (2020) Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS‐CoV‐2: an observational cohort study. Lancet Infect Dis 20: 565–574
Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A et al (2021) Interim findings from first‐dose mass COVID‐19 vaccination roll‐out and COVID‐19 hospital admissions in Scotland: a national prospective cohort study. Lancet 397: 1646–1657
Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E, Peterson P, Weckesser W, Bright J et al (2020) Author Correction: SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods 17: 352
Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R et al (2020) Safety and immunogenicity of two RNA‐based Covid‐19 vaccine candidates. N Engl J Med 383: 2439–2450
Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, Cipolla M, Hoffmann H‐H, Oliveira TY, Oren DA et al (2021) Enhanced SARS‐CoV‐2 neutralization by dimeric IgA. Sci Transl Med 13: eabf1555
Waskom ML (2021) seaborn: statistical data visualization. J Open Source Softw 6: 3021